Display options
Cite
Bleda S, De Haro J, Florez A, et al. Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease. Heart Asia. 2011;3(1):130-4doi: 10.1136/heartasia-2011-010045.
Bleda, S., De Haro, J., Florez, A., Varela, C., Esparza, L., & Acin, F. (2011). Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease. Heart Asia, 3(1), 130-4. https://doi.org/10.1136/heartasia-2011-010045
Bleda, S, et al. "Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease." Heart Asia vol. 3,1 (2011): 130-4. doi: https://doi.org/10.1136/heartasia-2011-010045
Bleda S, De Haro J, Florez A, Varela C, Esparza L, Acin F. Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease. Heart Asia. 2011 Jan 01;3(1):130-4. doi: 10.1136/heartasia-2011-010045. eCollection 2011. PMID: 27326011; PMCID: PMC4898577.
Copy Download .nbib Format: NLM
Share it on

Heart Asia. 2011 Jan 01;3(1):130-4. doi: 10.1136/heartasia-2011-010045. eCollection 2011.

Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease.

Heart Asia

S Bleda, J De Haro, A Florez, C Varela, L Esparza, F Acin

Affiliations

  1. Department of Vascular Surgery and Angiology, Getafe University Hospital, Getafe, Madrid, Spain.

PMID: 27326011 PMCID: PMC4898577 DOI: 10.1136/heartasia-2011-010045

Abstract

OBJECTIVES: Peripheral arterial disease can be regarded as a systemic inflammatory disorder affecting the entire vascular system. In the early clinical stages, it is characterised by the deterioration of endothelial function, which does not progress with the development of the disease. This study analyses the pleiotropic effects upon the plasma nitrite and C-reactive protein (CRP) levels in claudicating patients after 12 months of treatment with statins.

STUDY DESIGN: A prospective randomised controlled translational study was made in patients with Fontaine grade II ischaemia, treated with the best medical treatment with or without statins for 12 months from the time of diagnosis for assessing the pleiotropic effects of those statins.

METHODS: Measurements of plasma high-sensitivity CRP (hsCRP), lipid profile and nitrites were made at baseline and after 1 month and 1 year of treatment with atorvastatin 40 mg/day.

RESULTS: A significant reduction in nitrite levels was observed after 1 month of treatment (11.8±7.8 μM vs 5.7±1.8 μM, p=0.0001), but this effect did not persist after 1 year (11.8±7.8 μM vs 9.4±8.9 μM, p=0.27). HsCRP underwent a significant reduction after both 1 month (7 (2.2-12) vs 3.4 (1.6-5.5), p<0.01) and 1 year of treatment with atorvastatin (7 (2.2-12) vs 2.25 (1.67-6.7), p=0.02). Statin treatment reduced hsCRP levels in 9.64 (95% CI (1.60 to 17.68)) after 1 month and in 9.14 (95% CI (0.18 to 18.47)) after 1 year.

CONCLUSIONS: The long-term biological pleiotropic effects of statins provide information on the role of endothelial function and systemic inflammation in the aetiopathogenesis of peripheral arterial disease. Statins slow endothelial degradation at the start of the disease, with no effects over the long term. These drug substances reduce progressive inflammation throughout the treatment period. This supports the novel hypothesis that endothelial dysfunction is only a disease-triggering phenomenon, while systemic inflammation would be responsible for both the origin and the maintenance of peripheral arterial disease.

Keywords: Endothelium; aorta; endothelial function; gene therapy; great vessels and trauma; peripheral vascular disease

References

  1. Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):107-12 - PubMed
  2. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):176-82 - PubMed
  3. Clin Med Cardiol. 2008 Dec 23;3:1-7 - PubMed
  4. Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):538-45 - PubMed
  5. J Clin Lab Anal. 1998;12(3):137-44 - PubMed
  6. Circulation. 2002 Dec 17;106(25):3143-421 - PubMed
  7. Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):61-9 - PubMed
  8. J Cardiovasc Pharmacol. 1999 Dec;34(6):879-86 - PubMed
  9. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1398-404 - PubMed
  10. Life Sci. 2006 Jul 4;79(6):525-31 - PubMed
  11. Free Radic Biol Med. 2003 Oct 1;35(7):790-6 - PubMed
  12. Diabetes Care. 2003 Jan;26 Suppl 1:S5-20 - PubMed
  13. J Clin Invest. 2003 Jun;111(12):1805-12 - PubMed
  14. Circulation. 1998 Mar 31;97(12):1129-35 - PubMed
  15. Rev Esp Cardiol. 2003 Sep;56(9):843-7 - PubMed
  16. Circulation. 2005 Mar 29;111(12):1530-6 - PubMed
  17. Atherosclerosis. 2001 Jan;154(1):87-96 - PubMed
  18. Eur J Vasc Endovasc Surg. 2009 Apr;37(4):443-7 - PubMed
  19. J Am Coll Cardiol. 2003 May 21;41(10 ):1769-75 - PubMed
  20. N Engl J Med. 1999 Jan 14;340(2):115-26 - PubMed
  21. J Mol Cell Cardiol. 2007 Dec;43(6):780-91 - PubMed
  22. Eur J Vasc Endovasc Surg. 2008 Apr;35(4):480-6 - PubMed
  23. Circulation. 1999 Jul 20;100(3):230-5 - PubMed
  24. J Vasc Surg. 2003 Aug;38(2):374-9 - PubMed
  25. J Cardiovasc Pharmacol. 2007 Oct;50(4):391-8 - PubMed
  26. J Vasc Surg. 2004 Jul;40(1):187-93 - PubMed
  27. Methods Enzymol. 2002;359:158-68 - PubMed
  28. Hypertension. 2006 Jan;47(1):87-94 - PubMed
  29. Nefrologia. 2001;21 Suppl 5:18-20 - PubMed

Publication Types